LUMOXITI Canadian Trademark Information

On Thursday, March 29, 2018, a canadian trademark registration was filed for LUMOXITI by Innate Pharma S.A. *********, **********, ***** ****. The Canadian IP office has given the trademark application number of 1891028. The current status of this trademark filing is Registration published. The LUMOXITI trademark is filed in the description of Pharmaceutical preparations and substances for use in oncology and for the treatment of cardiovascular diseases and disorders, respiratory diseases and disorders, pharmaceutical preparations for use in gastroenterology; pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely, diabetes, hypoglycaemia, gout, osteoarthritis, anemia, obesity and hypothyroidism; pharmaceutical preparations for the treatment of diseases and disorders of the central nervous system, namely central nervous system infections, brain diseases, depression, anxiety, central nervous system movement disorders, and spinal cord diseases; pharmaceutical preparations and substances for the treatment of diseases and disorders of the peripheral nervous system, namely cranial and spinal neuropathies, autonomic neuropathies, sensorimotor neuropathies and plexopathies; pharmaceutical preparations and substances for use in pain control and local and general anesthetics; pharmaceutical preparations, namely, anti-inflammatories; pharmaceutical preparations, namely, anti-infective. , Pharmaceutical preparations and substances for use in oncology and for the treatment of cardiovascular diseases and disorders, respiratory diseases and disorders, pharmaceutical preparations for use in gastroenterology; pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely, diabetes, hypoglycaemia, gout, osteoarthritis, anemia, obesity and hypothyroidism; pharmaceutical preparations for the treatment of diseases and disorders of the central nervous system, namely central nervous system infections, brain diseases, depression, anxiety, central nervous system movement disorders, and spinal cord diseases; pharmaceutical preparations and substances for the treatment of diseases and disorders of the peripheral nervous system, namely cranial and spinal neuropathies, autonomic neuropathies, sensorimotor neuropathies and plexopathies; pharmaceutical preparations and substances for use in pain control and local and general anesthetics; pharmaceutical preparations, namely, anti-inflammatories; pharmaceutical preparations, namely, anti-infective. , Pharmaceutical preparations and substances for use in oncology and for the treatment of cardiovascular diseases and disorders, respiratory diseases and disorders, pharmaceutical preparations for use in gastroenterology; pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely, diabetes, hypoglycaemia, gout, osteoarthritis, anemia, obesity and hypothyroidism; pharmaceutical preparations for the treatment of diseases and disorders of the central nervous system, namely central nervous system infections, brain diseases, depression, anxiety, central nervous system movement disorders, and spinal cord diseases; pharmaceutical preparations and substances for the treatment of diseases and disorders of the peripheral nervous system, namely cranial and spinal neuropathies, autonomic neuropathies, sensorimotor neuropathies and plexopathies; pharmaceutical preparations and substances for use in pain control and local and general anesthetics; pharmaceutical preparations, namely, anti-inflammatories; pharmaceutical preparations, namely, anti-infective. .